Ophthalmology

Dr. Brian Marr Named Director of Ophthalmic Oncology at NewYork-Presbyterian/Columbia Medical Center

Dr. Brian Marr.​ NEW YORK—Dr. Brian Marr will join the department of ophthalmology at NewYork-Presbyterian/Columbia University Medical Center as director of the division of ophthalmic oncology, effective May 15. He will also serve as a professor of ophthalmology at Columbia University Medical Center, according to an announcement from the Medical Center. With Dr. Marr’s arrival, the Medical Center is establishing one of the largest and most comprehensive ocular melanoma programs in the country, the announcement said. Dr. Marr will be working alongside medical oncologists, in keeping with NewYork-Presbyterian/Columbia University Medical Center’s team-based approach to cancer care. Prior to joining NewYork-Presbyterian/Columbia,…


Georgia Governor Signs Legislation Authorizing ODs to Administer Some Injections

ATLANTA—Georgia Gov. Nathan Deal last week signed legislation that will allow optometrists to perform certain types of injections in and around the eye. The legislation, Senate Bill 153, will improve access to eyecare treatment and enable Georgia to “continue to attract top-tier medical talent,” according to a statement from the Georgia Optometric Association (GOA), which supported the legislation. The bill was approved by a 30-21 vote in the Senate and by a 121-36 vote in Georgia’s House of Representatives, according to GOA. There are now more than 15 states, including Georgia neighbor Tennessee, that authorize ODs to perform limited injections…


Bill Hughson Named CEO of Grand Rapids Ophthalmology

Bill Hughson.​ GRAND RAPIDS, Mich.—Grand Rapids Ophthalmology (GRO)— a comprehensive eyecare provider offering ophthalmology, optometry and retail optical services in West Michigan—announced today the appointment of Bill Hughson as chief executive officer. “It’s clear that GRO’s longevity, the quality of its doctors and staff and its recent partnership with Great Lakes Management Services Organization (Great Lakes MSO) have uniquely positioned GRO to rapidly and strategically grow, and provide the best patient care to individuals and families throughout West Michigan,” said Hughson. “I look forward to working with the GRO team as we begin our next chapter.” Prior to GRO, Hughson…


Second Sight Posts Losses in First Quarter 2017

SYLMAR, Calif.—Second Sight Medical Products (NASDAQ:EYES), maker of the Argus II retinal prosthesis, posted losses for the three months ended March 31, 2017, despite an increase in implant volume of the device. Second Sight reported that 14 Argus II Retinal Prosthesis Systems were implanted worldwide during the first quarter of 2017 compared to seven in the fourth quarter of 2016 and 10 in the first quarter of 2016. However, the company’s net sales in the first quarter of 2017 were $1.0 million compared to $1.1 million in the first quarter of 2016, which represents revenue per implant of $72,000 in…


LensGen Closes $21 Million Financing Round, Led by Hoya

IRVINE, Calif.—LensGen, a private company developing Juvene, a modular, fluid-optic accommodating intraocular lens, announced that it has closed a $21 million Series A financing. The round was led by the corporate venture investment arm of Hoya Group. Hoya’s medical division produces intraocular lenses and other medical-related products. Relativity Healthcare Partners also participated in the financing, which includes an option to expand the financing commitment by an additional $5 million, LensGen said in a statement. “We are pleased to attract an experienced ophthalmology and corporate strategic investor like Hoya to accelerate our efforts to further develop and bring to market this…